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Early detection and appropriate management of chronic kidney disease can reduce the
progression of kidney failure and cardiovascular disease. The urine albumin to creatinine
ratio (UACR) test is a standard urine test for identifying individuals at high risk of
developing progressive kidney disease. In this study, IDATPE, a novel ﬂuorescent probe
with aggregation-induced emission (AIE) features, is successfully developed for
creatinine detection and quantitation. An excellent correlation between ﬂuorescent light
intensity and creatinine concentration is achieved. In addition, BSPOTPE, a reported
excellent AIE bioprobe for human serum albumin (HSA) quantitation, is used together
with IDATPE in artiﬁcial urine for UACR testing. The mutual interference of HSA and
creatinine when the bioprobes are used for quantitation is characterised, with promising
results. Further improvements and potential applications in CKD quantitation are
highlighted.1. Introduction
Chronic kidney disease (CKD), a condition characterised by a progressive loss of
kidney function over time, is a signicant and growing public health problem
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View Article Onlineprematuremortality. According to US National Kidney Foundation research, more
than 20 million Americans, 1 of 9 adults, have CKD and another 20 million more
Americans are at increased risk.1 Each year in the US, more than 100 000 people
are diagnosed with kidney failure.2 In Australia, one-third of Australians are at
risk of developing CKD. In addition, more than 40% of people over the age of 75
have an indicator of this disease. As a result, approximately 2300 newly diagnosed
individuals are required to commence either dialysis or kidney transplantation
each year in Australia.3 Furthermore, CKD patients have a 2- to 3-fold greater risk
of cardiac death than age- and sex-matched controls without CKD.4 Therefore,
CKD directly or indirectly contributes to about 10% of Australians deaths and is
one of the few diseases in which mortality rates are worsening over time.4 More
worrying is that many people are unaware of these risks in many cases. A person
can lose up to 90 percent of their kidney function before experiencing any
symptoms. Diabetes and high blood pressure are two of the most common causes
of CKD, accounting for up to two-thirds of the cases. Individuals who suﬀer from
obesity, have a history of heart attack or stroke or a family history of CKD or
smoking also have an increased risk of developing CKD.1,4
Early detection and appropriate management of CKD can reduce the
progression of kidney failure and cardiovascular disease by up to 50 percent.
Clinical practice guidelines in Europe, the USA and Australia have recommended
that the test for urine albumin to creatinine ratio (UACR) should be used, in
addition to the test for estimated glomerular ltration rate (eGFR), to screen for
CKD and its prognostic grading.5–7 HSA is the most abundant serum protein with
a concentration of approximately 35–50 g L1.8 However, in the case of kidney
damage, small amounts of albumin leak into the urine, leading to a condition
dened as microalbuminuria that can cause elevated albumin levels of up to 300
mg mL1 in urine. Thus, microalbuminuria testing is typically employed as an
initial screening tool for kidney disease.9 In the past, the urine albumin excretion
was determined by albumin excretion rate in a 24 hour collection.10 Due to the
diﬃculty of collecting 24 hour urine samples, it has now been recommended to
determine urine albumin by measuring UACR on a spot sample, especially the
rst morning void.10,11 The current clinical routine measurement procedures for
urine albumin are dominated by immunoassays, among which most are immu-
noturbidimetric.10 Although having a detection limit at 2–10 mg L1,12 immu-
noassays tend to underestimate the amount of albumin in urine. This is due to
the fact that albumin has at least ve antigenic sites and the existence of various
forms of albumin (truncated and modied forms) in urine have increased the
diﬃculty for the antibodies to detect all the forms of albumin. Dipstick, high
performance liquid chromatography (HPLC), liquid chromatography-mass spec-
trometry (LC-MS) and liquid chromatography-tandemmass spectrometry (LC-MS/
MS) are also used as alternative methods.13 Although HPLC gives higher albumin
detection values than immunoassays, it is believed that this is due to the detec-
tion of other (proteins) molecules with similar sizes to albumin.12 Although
LC-MS can precisely detect intact albumin and albumin fragments with an intact
N-terminus, it is not able to detect albumin fragments lacking the N-terminus.
LC-MS/MS has high detection sensitivity (<25 mg L1) and is able to detect intact
albumin as well as albumin fragments, however post-translational modications
on albumin may aﬀect the detection.13 Dipstick is widely used as an initial352 | Faraday Discuss., 2017, 196, 351–362 This journal is © The Royal Society of Chemistry 2017
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View Article Onlinescreening for CKD due to its low cost. However, it is a semiquantitative colori-
metric test with a detection limit of 150 mg L1.12
Creatinine is one of the most common biomarkers and the end metabolic
product of creatine in mammals. The determination of creatinine concentration
in biological uids is important in the evaluation of renal function and muscle
damage.14,15 Normal physiological creatinine concentrations in serum are in the
range of 35 to 140 mM. Increased creatinine concentration leads to diabetic
nephropathy, preeclampsia, glomerulonephritis, urinary tract obstruction and
renal failure, while decreased creatinine concentration leads to muscular
dystrophy and myasthenia.14 Therefore, the determination of creatinine in
human plasma or urine is of great importance from a biological and clinical
viewpoint. Furthermore, creatinine is normally released into the urine at
a constant rate, and thus its level in urine is an indication of the urine concen-
tration, allowing its measurement to be used to correct for urine concentration in
a random urine sample in clinical urine tests such as UACR. Urine creatinine
measurement is routinely done using clinical analyzers based on the colorimetric
Jaﬀe rate reaction.16,17 The lower detection limit is at approximately 10 mgmL1. In
this reaction, the active methylene group of creatinine reacts with alkaline solu-
tions of sodium picrate to yield an orange-yellow complex with a maximum
absorbance at 510 nm. Despite its simplicity, this method is time-consuming and
not very selective, because several substances can form coloured species with the
alkaline picrate.18 These compounds include glucose, albumin, cycloketones and
carbonyl compounds.20 Other not commonly used creatinine detection methods
include capillary electrophoresis, liquid chromatography (LC), gas chromatog-
raphy (GC), GC-MS, and GC-MS/MS. Although some of these methods have
attained limits of detection down to 1–100 ng mL1, they are not practical for
routine urinary creatinine determination due to sample throughput, technical
complexity and aﬀordability.19,20
Biosensors based on uorescent materials have attracted much attention due
to their sensitivity, selectivity and rapidity. Organic molecules and organometallic
complexes have been developed for protein assays. Upon complexation or
conjugation with proteins, the luminophores show emission changes and/or
spectral shis, enabling biopolymers to be detected and quantied.21,22 Some
uorescence probes are insoluble in aqueous media, while others are unstable
under ambient conditions. Some luminophores show spectacular performance in
protein assays but are extremely expensive because of their painstaking syntheses.
These drawbacks greatly limit the scope of their real-life high-tech applica-
tions.23,24 This situation calls for the development of synthetic, readily accessible
and environmentally stable bioprobes with high sensitivity and selectivity. A
thorny problem associated with the emission quenching of conventional lumi-
nophores in aqueous medium or physiological buﬀer is aggregation-caused
quenching (ACQ).25 ACQ luminophores mostly have planar structures and are in
close vicinity in aggregates suspended in the aqueous buﬀer, phenomena that can
easily generate p–p stacking and cause non-radiative relaxation of the excited
states. We have recently discovered that the propeller-like tetraphenylethene
(TPE) structure behaves in a manner exactly opposite to the ACQ dyes: it is non-
emissive in the solution state but becomes highly luminescent in the aggregate
state. We coined the term “aggregation-induced emission” (AIE) for the
phenomenon because the non-emissive TPE is induced to emit by aggregateThis journal is © The Royal Society of Chemistry 2017 Faraday Discuss., 2017, 196, 351–362 | 353
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View Article Onlineformation.26–28 Decorating TPE with ionic or polar functional groups yields water
soluble derivatives which can be utilized as uorescence probes for bioanalyses.
Our research group and others have successfully used TPE-based AIE luminogens
for human serum albumin (HSA) detection and quantication.29,30 BSPOTPE
(sodium 1,2-bis[4-(3-sulfonatopropoxyl)phenyl]-1,2-diphenylethene) has demon-
strated superior sensitivity, as low as 1 nM, against albumin detection.29 It also
showed an excellent specicity to HSA and bovine serum albumin (BSA) when
several other human proteins, such as pepsin, human immunoglobulin G (IgG),
etc., were present.29 These successes prompted and motivated us to further
explore the potential of TPE-based AIE luminogens in bioanalyses for creatinine
quantication31 and UACR determination.
In this study, we examined the utility of the TPE salts IDATPE (iminodiacetic
acid functionalised TPE) and BSPOTPE as bioprobes for creatinine and HSA
detection and quantitation. The potential mutual interference of creatinine and
HSA in articial urine during detection and quantitation was also evaluated for
UACR applications.
2. Materials and methods
2.1 Chemicals
All of the reagents used in this study were purchased from Sigma-Aldrich unless
otherwise specied. BSPOTPE was prepared according to previously published
procedures29,32 and IDATPE was synthesized and characterised before use in this
study (Chart 1).
2.2 Sample preparation
IDATPE was dissolved in 100% acetonitrile (ACN) to make a 25 mM stock solu-
tion. BSPOTPE was prepared according to published procedures.32 A stock solu-
tion of BSPOTPE with a concentration of 5.0 mM was prepared by dissolving an
appropriate amount of dye in Milli-Q lab water (Millipore, Billerica, MA). Both of
the stock solutions were stored in the dark at 4 C before use. Working solutions
of both dyes were prepared daily by suitable dilution of the stock solution with
either deionized water or articial urine. The articial urine solution was
prepared by following the procedure previously published.33
Stock solutions of creatinine and HSA were prepared using either deionized
water or articial urine to a concentration of 1 M and 30 mM, respectively.
Working solutions were prepared freshly by appropriate dilution of the stock
solution.Chart 1 Chemical structures of AIE luminogens IDATPE and BSPOTPE.
354 | Faraday Discuss., 2017, 196, 351–362 This journal is © The Royal Society of Chemistry 2017
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View Article Online2.3 Characterisation
Steady-state uorescence spectra were recorded using a Varian Cary Eclipse
Fluorimeter (Varian Australia Pty Ltd). All pH adjustments were carried out using
a digital pH meter (Hanna pH meter, mode: HI 208-02).
2.3.1 AIE features of IDATPE. Appropriate amounts of IDATPE stock solution
were diluted with ACN as well as diﬀerent volume portions of water (10%, 20%,
40%, 60%, 80% and 90%) to a nal concentration of 40 mM. The solutions were
incubated at room temperature for 5 min, followed by photoluminescence (PL)
measurement using the uorimeter with an excitation wavelength of 262 nm and
an emission wavelength of 375 nm. FL spectra were also measured in 40 mM
IDATPE diluted from 25 mM stock solution described previously with diﬀerent
pH (pH 6–12) solutions which were adjusted using diﬀerent concentrations of
NaOH and HNO3 solutions.
2.3.2 Eﬀect of creatinine on IDATPE. IDATPE was mixed with diﬀerent
concentrations of creatinine solution made in water or articial urine to a nal
concentration of 40 mM. Aer incubation of the mixture at room temperature for 5
min, the FL intensity was measured at 375 nm with the excitation wavelength at
262 nm.
2.3.3 Eﬀects of HSA on IDATPE and creatinine on BSPOTPE. To evaluate the
eﬀect of existing HSA in articial urine on the IDATPE detection of creatinine,
IDATPE was mixed with diﬀerent concentrations of creatinine solution in arti-
cial urine with 3.6 mM HSA to a nal concentration of 40 mM. Aer incubation of
the mixture at room temperature for 5 min, the PL was recorded with the exci-
tation wavelength at 262 nm. The FL intensity was measured at 375 nm and
460 nm.
To evaluate the eﬀect of existing creatinine in articial urine on the BSPOTPE
detection of HSA, BSPOTPE was mixed with diﬀerent concentrations of HSA
solution made in articial urine with or without 30 mM creatinine, to a nal
concentration of 40 mM. Aer incubation of the mixture at room temperature for
5 min, the FL intensity was measured at 475 nm with 350 nm as the excitation
wavelength.3. Results and discussion
3.1 Dye synthesis and characterisation
IDATPE was prepared by the synthetic route shown in Scheme S1 in the ESI.† The
reaction intermediates and nal product were fully characterised by spectroscopic
methods from which satisfactory analysis data were obtained (see the charac-
terisation data in the ESI†).3.2 Aggregation-induced emission feature of IDATPE
IDATPE is AIE-active, as shown in Fig. 1 and S2.† The ACN solution of IDATPE
emits a faint UV light at a concentration of 40 mM. When water was added as
a poor solvent while keeping the concentration of IDATPE constant, the resultant
mixture showed an increasing uorescence peak at 375 nm. The greatest
enhancement of this peak was recorded when the water fraction reached 60%.
Due to the hydrophilic environment of the ACN/water, organic soluble IDATPE
molecules aggregated and restricted the rotation of the phenyl rings. Hence,This journal is © The Royal Society of Chemistry 2017 Faraday Discuss., 2017, 196, 351–362 | 355
Fig. 1 FL intensities in diﬀerent water/acetonitrile ratios. lex¼ 262 nm; [IDATPE]¼ 40 mm.
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View Article Onlinenon-radiative decay was blocked and the radiative relaxation was open, granting
its highly emissive property. However, a small decrease in the FL intensity aer
ACN/water reached 60% was observed, probably caused by crystallization or
precipitation of this bioprobe.
The eﬀect of pH on the FL spectra of IDATPE was investigated and is shown in
Fig. 2 and S3.† Because hydrogen bonding may be the major interaction (see
Chart 2) between IDATPE and creatinine, the eﬀect of the pH of the solution was
investigated in a pH range of 6 to 12. As can be seen from Fig. 2, no obvious FL
intensity change was found at pH 6 to 10. It is reasonable to believe that aer pH
10, the iminodiacetic acid (IDA) group chelated the sodium ion and formed
clusters which started to decrease the FL intensity. The sensitivity of IDATPE
decreased in the presence of sodium and other metal ions, such as potassium,
calcium, and magnesium, at alkaline pH because these ions can shield or
protonate the negative charges of the carboxyl groups of IDA due to the chelatingFig. 2 FL intensities at 375 nm with pH values; lex ¼ 262 nm; [IDA-TPE] ¼ 40 mm.
356 | Faraday Discuss., 2017, 196, 351–362 This journal is © The Royal Society of Chemistry 2017
Chart 2 Schematic illustration of the possible mechanism of aggregation of IDATPE in the
presence of creatinine.
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View Article Onlineeﬀect at alkaline pH.34 The pH value of 6.2 was selected for subsequent studies.
This is because the human urine pH range is between 5.5 and 7, with average of
6.2.35 Under this pH, the metal ions present won't interfere with IDATPE to reduce
its sensitivity.3.3 Creatinine quantitation in solution
Creatinine has two diﬀerent tautomeric forms with similar energy that can bind
to other molecules through hydrogen bond donor–acceptor arrays.30 The IDATPE
easily coordinated with creatinine via hydrogen bond formation between the NH
group of creatinine and the –COO group of IDA, as shown in Chart 2, with the
result that a large group was attached to the TPE core and restricted the rotation
of the phenyl rings. Therefore, the change of uorescence intensity can be utilized
as a simple and selective method for the determination and possible quantitation
of creatinine.
To examine the feasibility of the creatinine assay, creatinine quantitations in
water and in articial urine were performed. The IDATPE solutions in water and
articial urine were both luminescent at 375 nm in the absence of creatinine. In
both uids, the trends of IDATPE for creatinine quantitation are similar, as shown
in Fig. 3(a), but a signicant decrease in FL intensity is clearly observed in the
articial urine, which may attributable to the presence of other chemicals (ESI
Table S1 and Fig. S4†) such as CH4N2O and C5H4N4O3 interacting with the
IDATPE and signicantly decreasing the FL intensity. An IDATPE concentration of
40 mM was chosen in this study. The eﬀect of the incubation time of IDATPE with
creatinine was studied. The FL intensity increased in the rst 5 minutes and
remained constant for 10 minutes (ESI Fig. S5†), so a duration of 5 minutes was
chosen for the measurement. When the incubation time increased, the FL
intensity again decreased, but the FL intensity measured at diﬀerent times fol-
lowed the same trend as the increase in creatinine concentration (ESI Fig. S6†).
As shown in Fig. 3(a), when a small amount of creatinine is added, the FL
intensity of the IDATPE solution increases. Its FL intensity at 375 nm continued to
rise with an increase in creatinine concentration up to100 mM and50 mMwith
an IDATPE concentration of 40 mM in articial urine and water, respectively. TheThis journal is © The Royal Society of Chemistry 2017 Faraday Discuss., 2017, 196, 351–362 | 357
Fig. 3 (a) FL intensities at 375 nmwith creatinine concentration in water and artiﬁcial urine
and (b) zone I region in water and artiﬁcial urine. lex ¼ 262 nm; [IDATPE] ¼ 40 mM;
measured at t ¼ 5 min.
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View Article Onlinerates of the FL enhancement in those regions are almost constant. In the creat-
inine concentration range of 0–100 mM for articial urine and 0–50 mM for water
(zone I), the plot of FL intensity as a function of the logarithm of creatinine
concentration is a linear line with a high correlation coeﬃcient (Fig. 3(b)). With
a further increase in creatinine concentration (zone II, 100 mM to 2 mM for
articial urine and 50 mM to 1 mM for water) while keeping the IDATPE
concentration at 40 mM, the FL intensity is constant, indicating that IDATPE
molecules have been consumed/bound with creatinine completely and there is
a small amount of extra creatinine within the solution. If the creatinine
concentration is further increased to 70 mM (zone III, 2–70 mM for articial urine
and 1–70 mM for water), the FL intensity continues to decrease. The IDATPE and
creatinine formed large nanoparticles and precipitated in the solution, which
caused the FL intensity to decrease continuously.358 | Faraday Discuss., 2017, 196, 351–362 This journal is © The Royal Society of Chemistry 2017
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View Article OnlineSensitivity analysis of IDATPE for creatinine detection in water and articial
urine is shown in Fig. 3(b). It can be seen that IDATPE is more sensitive (slope ¼
90.493) to the change of creatinine concentration in water than (slope¼ 24.152) in
articial urine. In the real-life application, however, urine is the solution for
UACR calculation, so articial urine was selected for the next study.3.4 Mutual interference between creatinine and HSA in articial urine
Clinically, HSA and creatinine both exist in urine, and albumin is known to
interfere with colorimetric Jaﬀe rate reaction based routine creatinine assays,20
thus the mutual interference of the two species when detected by TPE bioprobes
needs to be evaluated. A value of UACR > 30 mg g1 may be a sign of CKD.
Microalbuminuria is a term used to describe urine albumin levels not detected by
a dipstick test, i.e., UACR is within 30–300 mg g1. Under normal conditions, the
molecular weight ratio of HSA/creatinine should be in the 104 order of magni-
tude (see ESI†), as shown in eqn (1). Higher molecular weight ratios may indicate
a potential CKD risk. Therefore, the eﬀects of a xed concentration of HSA on
creatinine detection by IDATPE and a xed concentration of creatinine on HSA
detection by BSPOTEP were evaluated in this study, with the molecular weight
ratio of HSA/creatinine in the range of 101 to 104 to reect clinical requirements.
Urine albumin ðmg dL1Þ
Urine creatinine ðg dL1Þ ¼ UACR

mg g1

(1)
3.4.1 Interference of HSA in creatinine detection by IDATPE. A concentration
of 3.6 mMHSA was added to the articial urine for the interference study, in which
3.6 mM HSA was calculated in accordance with UACR 30 mg g1 and the female
urine creatinine normal range starting level of 70 mM (70–158 mM). The inter-
ference of HSA in creatinine detection by IDATPE is shown in Fig. 4 with detailed
FL spectra (ESI Fig. S7†). From Fig. S7,† it is clearly evident that two distinctiveFig. 4 FL intensities at 375 nm with diﬀerent concentrations of creatinine and creatinine
containing 3.6 mMHSA in artiﬁcial urine. lex¼ 262 nm; [IDATPE]¼ 40 mm; measured at t ¼
5 min.
This journal is © The Royal Society of Chemistry 2017 Faraday Discuss., 2017, 196, 351–362 | 359
Fig. 5 FL intensities at 475 nm with diﬀerent concentrations of HSA and HSA containing
30 mM creatinine in artiﬁcial urine. lex ¼ 350 nm; [BSPOTPE] ¼ 40 mm; measured at
t ¼ 5 min.
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View Article Onlinepeaks appear at 375 nm and 460 nm, resulting from the eﬀects of creatinine and
HSA on IDATPE. Comparison in Fig. 4 of the creatinine concentration eﬀects on
IDATPE FL intensity with and without HSA shows that the two curves have the
same trend. However, with HSA interference, the FL intensities at 375 nm
signicantly increase. The FL intensities at 460 nm were also recorded and are
plotted here, showing a similar trend.
3.4.2 Interference of creatinine in HSA detection by BSPOTPE. A concentra-
tion of 30 mM creatinine was added to the articial urine for the interference
study. The interference of creatinine in HSA detection by BSPOTPE is shown in
Fig. 5. The two curves in Fig. 5 do not show a signicant diﬀerence, fromwhich we
may conclude that creatinine in the range of 5–70 mMhad no signicant eﬀect on
HSA detection in the range of 0–16 mM by BSPOTPE. The clear linear relationship
between FL light intensity and HSA concentration is still valid, and has been
demonstrated previously.294. Conclusions
Chronic kidney disease (CKD) is a signicant and growing public health problem
throughout the world. Urine albumin-creatinine ratio (UACR) is a urine test that
measures the ratio of urine albumin and urine creatinine and is used to stan-
dardise urine albuminmeasurements to indicate the presence CKD. In this study,
a novel bioprobe with aggregation-induced emission (AIE) features, IDATPE, was
used to detect and quantitate creatinine in water and articial urine. An excellent
correlation between FL light intensity and creatinine concentration was achieved
within a certain range. IDATPE was also used with BSPOTPE, another bioprobe
with AIE features, for human serum albumin (HSA) detection and quantitation to
evaluate the mutual interference when these bioprobes were used together in
articial urine for creatinine and HSA analysis. Promising results were achieved
and further evaluation is needed to gain more understanding of the IDATPE360 | Faraday Discuss., 2017, 196, 351–362 This journal is © The Royal Society of Chemistry 2017
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View Article Onlinebioprobe for creatinine detection and of mutual interference in urine when AIE
bioprobes are used for UACR calculation.
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